Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Clinical trial NCT07304739 · RECRUITING
Trial details
- NCT number
- NCT07304739
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-22
- Primary completion
- 2028-12-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.